1-6 of 6
Matthias Mayerhofer, M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Identification Of The Ki-1 Antigen (CD30) As a Novel Marker and Potential Therapeutic Target In Neoplastic Mast Cells In Advanced Systemic Mastocytosis

Katharina Blatt, MSc, Ph.D., Sabine Cerny-Reiterer, D.V.M, Karl Sotlar, M.D., Schwaab Juliana, M.D., Gregor Hoermann, M.D., Ph.D., Matthias Mayerhofer, M.D., Emir Hadzijusufovic, DVM, Michael Willmann, D.V.M., Andreas Reiter, MD, Hans-Peter Horny, MD, Peter Valent
Journal: Blood
Blood (2013) 122 (21): 3773.
https://doi.org/10.1182/blood.V122.21.3773.3773
Published: 2013
Journal Articles

Identification of Campath-1 Antigen (CD52) As a Novel Therapeutic Target in Advanced Systemic Mastocytosis.

Gregor Hoermann, M.D., Ph.D., Katharina Blatt, MSc, Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Leonhard Müllauer, M.D., Peter Valent, MD, Matthias Mayerhofer, M.D.
Journal: Blood
Blood (2012) 120 (21): 2866.
https://doi.org/10.1182/blood.V120.21.2866.2866
Published: 2012
Journal Articles

The Leukemic Stem Cell (LSC) in Ph + CML Is a CD34 + /CD38 − /Lin − Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1α

Harald Herrmann, M.D., Irina Sadovnik, M.Sc., Sabine Cerny-Reiterer, D.V.M., Katharina Blatt, M.Sc., Viviane Ghanim, M.D., Susanne Herndlhofer, Gregor Hoermann, M.D., Thomas Rülicke, D.V.M., Michael Willmann, D.V.M., Gerlinde Mitterbauer-Hohendanner, M.D., Matthias Mayerhofer, M.D., Wolfgang R. Sperr, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2011) 118 (21): 961.
https://doi.org/10.1182/blood.V118.21.961.961
Published: 2011
Journal Articles

Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib

Karoline V. Gleixner, MD, Matthias Mayerhofer, M.D., Uwe Rix, Ph.D., Gregor Hoermann, Alexander Gruze, Maria-Theresa Krauth, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Giulio Superti-Furga, Ph.D., Peter Valent, M.D.
Journal: Blood
Blood (2007) 110 (11): 1541.
https://doi.org/10.1182/blood.V110.11.1541.1541
Published: 2007
Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.

Veronika Ferenc, MD, Karoline V. Gleixner, M.D., Alexander Gruze, M.D., Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2007) 110 (11): 3554.
https://doi.org/10.1182/blood.V110.11.3554.3554
Published: 2007
Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition.

Karoline V. Gleixner, MD, Veronika Ferenc, M.D., Alexander Gruze, Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2007) 110 (11): 1046.
https://doi.org/10.1182/blood.V110.11.1046.1046
Published: 2007